Association Between Open Payments–Reported Industry Transfers of Value and Prostaglandin Analog Prescribing in the US

Nguyen, Angeline; Anderson, Kelly E.; Anderson, Gerard F.; Johnson, Thomas V.

doi:10.1001/jamaophthalmol.2022.2757

Cited by 9 publications

(17 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, the authors point out that other research has not shown an increase in clinical effectiveness or reduction in adverse effects with the newer branded PGAs compared with the generic. 1 The authors also note that data suggests that patients who are prescribed the lower-cost generic…”

Section: Invited Commentarymentioning

confidence: 99%

“…Small Payments, Large Consequences Roni M. Shtein, MD, MS; Paul R. Lichter, MD, MS; Paul P. Lee, MD, JD In this issue of JAMA Ophthalmology, Nguyen et al 1 report on the potential association of industry payments to optometrists and ophthalmologists with the prescription of branded to generic prostaglandin analogs (PGA) for treating glaucoma. In their retrospective Medicare database analysis, the authors elegantly combined drug prescribing information from the US Centers for Medicare & Medicaid Services (CMS) Part D beneficiary database with CMS Open Payments data about industry payments using a ProPublica crosswalk to align prescriber information between the 2 databases.…”

Section: Invited Commentarymentioning

confidence: 99%

“…The article's discussion provides some context about the social psychology concepts that contribute to this phenomenon, including implicit bias. 1 As the authors noted, studies have shown that physicians routinely underestimate their vulnerability to being influenced and continue to be unaware of the ways that these influences then change their practice behaviors. 4 The potential implications of this study extend to at least 4 key areas.…”

Section: Related Article Page 855mentioning

confidence: 99%

“…Second, given the empirical confirmation of the association of even low levels of payment with higher prescriptions of branded payments, this will provide impetus to further assess other means of influencing prescriber behavior beyond the mandatory reporting noted in this study. 1 One example is the drug samples provided to prescribers. Those are not reported by industry.…”

Section: Related Article Page 855mentioning

confidence: 99%

“…These are both ways in which industry can exert substantial influence toward the prescribing of branded medications. 6 Nguyen et al 1 were only able to study industry's required reporting of gifts to prescribers, meaning that other potential influencers of prescribing behavior are left to future investigation.…”

Section: Related Article Page 855mentioning

confidence: 99%

See 4 more Smart Citations

Small Payments, Large Consequences

2022

View full text Add to dashboard Cite

show abstract

Section: Invited Commentarymentioning

confidence: 99%

Section: Invited Commentarymentioning

confidence: 99%

Section: Related Article Page 855mentioning

confidence: 99%

Section: Related Article Page 855mentioning

confidence: 99%

Section: Related Article Page 855mentioning

confidence: 99%

See 3 more Smart Citations

Small Payments, Large Consequences

2022

View full text Add to dashboard Cite

show abstract

Challenges of Assessing Disclosure Accuracy—All We Have Is Our Integrity

Gottlieb

2023

JAMA Ophthalmol

View full text Add to dashboard Cite

Financial interests of any magnitude have been shown to influence physician behavior, with potentially significant impacts on clinical practice. Over the last decade, scientific and medical societies, journals, and medical research organizations have devoted a great deal of effort to promoting transparency with regard to financial conflicts of interest (COIs). A consensus has emerged in the biomedical community that transparency (buyer beware) should be the minimal standard observed to ensure that consumers of research, practice guidelines, and other professional output are aware of potential biases on the part of authors. Some recommendations go further, positing that in certain cases, researchers and authors should have no COIs.So it would appear disappointing that, as Nyugen et al 1 report in JAMA Ophthalmology, based on a comparison with data published in the CMS Open Payments website, 2 a large percentage of the authors of 24 American Academy of Ophthalmology (AAO) clinical practice guidelines published between 2016 and 2020 failed to disclose their financial interests accurately or at all in connection with guideline development.The study authors point out that practice guidelines (AAO terms them preferred practice patterns) can directly impact patient care, making the importance of transparency on the part of guideline authors all the more critical.There are some important limitations to the study, however. AAO's COI policy 3 and the Council of Medical Specialty Societies Code for Interactions with Companies, to which AAO has signed on, require guideline authors to disclose direct financial relationships to AAO. Consistent with the Council of Medical Specialty Societies code, AAO's COI policy indicates that relevant financial interests will be identified, mitigated, and/or disclosed, depending on the nature of the activity and an individual's role. Notably, each of the AAO's published clinical practice guidelines states, "In compliance with the Council of Medical Specialty Societies' Code for Interactions with Companies…relevant relationships with industry are listed." 4,5 Therefore, one must infer that when a guideline author is listed as having no financial relationships to disclose, a determination was made that none of the guideline author's financial interests was relevant to the subject matter of the guideline. It is unknown whether some guideline authors failed to disclose any direct financial relationships with companies, even if they received payments as reported in the Open Payments website; whether the relationships that were disclosed to AAO were determined not to relate to the content of the guideline; or whether the relationships were judged de minimus and therefore not relevant. (Many COI policies set a minimum threshold for disclosure that is higher than the Open Payments data, which publishes payments over $10.

show abstract